Loading company
Lifecore Biomedical, Inc. DE
LFCR · Nasdaq · ·
$6.58+0.9%Sep 29 close
- 1M
- +44.9%
- 6M
- +73.6%
- 1Y
- -10.6%
- 5Y
- -36.4%
LFCR · Nasdaq · ·
$6.58+0.9%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toFeb 28, 2025 | Change |
|---|---|---|---|
| Total Revenue | $34.2M | $35.2M | -2.81% |
| Profit | -$6.2M | -$14.8M | +58.32% |
| Profit per share | -$0.19 | -$0.42 | +54.76% |
| Free Cash Flow | -$2.7M | -$4.3M | +36.53% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Lifecore Biomedical, Inc. DE has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Lifecore Biomedical, Inc. DE’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.